KCK LTD.

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Reported portfolio value by quarter (12 quarters reported)

$142M $10.5M

Q4 21 Q3 22 Q2 23 Q1 25 Q3 25

$142M in Q4 2021 → $15.1M now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2025. Activity is the change in share count since the prior quarter's filing.

Holding	% of portfolio	Activity	Shares	Value
Sight Sciences Inc	99.7%	Unchanged	4,374,975	$15M
RT Rein Theraputics Inc	0.3%	Unchanged	22,341	$52.1K

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

quarter ended September 30, 2025 · filed October 14, 2025

No position changes this quarter.

quarter ended June 30, 2025 · filed July 08, 2025

No position changes this quarter.

quarter ended March 31, 2025 · filed July 11, 2025

Company	Action	Shares changed	Value of change	% of portfolio
Neuropace Inc	Exited	−5,270,845	−$59M	—

quarter ended December 31, 2024 · filed January 15, 2025

Company	Action	Shares changed	Value of change	% of portfolio
Neuropace Inc	Trimmed	−350,266	−$3.92M	78.7%
Sight Sciences Inc	Trimmed	−271,891	−$990K	21.2%

quarter ended September 30, 2023 · filed November 01, 2023

Company	Action	Shares changed	Value of change	% of portfolio
Sight Sciences Inc	Trimmed	−4,299	−$14.5K	22.2%

quarter ended June 30, 2023 · filed July 25, 2023

Company	Action	Shares changed	Value of change	% of portfolio
Sight Sciences Inc	Trimmed	−64,397	−$533K	60.4%

quarter ended March 31, 2023 · filed May 05, 2023

Company	Action	Shares changed	Value of change	% of portfolio
Sight Sciences Inc	Trimmed	−60,670	−$530K	61.2%

quarter ended December 31, 2022 · filed January 31, 2023

Company	Action	Shares changed	Value of change	% of portfolio
AT Aileron Therapeutics, Inc.	Exited	−446,817	−$101K	—
AT Aileron Therapeutics Inc	New	+22,341	+$52.9K	0.1%

Comments